Compare Paycom Software Inc (PAYC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Paycom Software Inc trades at $139 (market cap $6.72B), while Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 10.5× Paycom Software Inc's market cap, and Paycom Software Inc pays the higher dividend (1.04%). Which is the better fit depends on your goals.
| PAYC | REGN | |
|---|---|---|
Market Cap | $6.72B | $70.79B |
Sector | Technology | Health |
52-Week High | $238.80 | $812.27 |
52-Week Low | $113.59 | $545.46 |
Enterprise Value | $7.33B | $64.74B |
Dividend Yield | 1.04% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $144.22, down 2.51% today, with a bullish technical signal and strong fundamentals including 22.44% net margin and 37.15% ROE. Recent earnings beat expectations in Q1 2026, and the company launched a new Asset Management tool. Cash flow from operations grew to $679M in 2025, though net cash flow declined from 2024's peak.
Outlook remains positive with analyst consensus near current price ($144.60 target) and 47% buy ratings. Risks include high P/B of 8.6 and reliance on HR software demand. The stock offers value with a reasonable P/E of 17.33 but faces execution risks in maintaining growth against competition.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
